Hyperkalemia Treatment Market, by Drug Type (IV Calcium, Insulin, Sodium Bicarbonate, Beta2 Agonist, Diuretics, Sodium Polystyrene Sulfonate, Others), by Route of Administration (Oral and Intravenous, Inhalation, Rectal)
Hyperkalemia is a diseases in which levels of potassium are higher than normal level (3.5 and 5.0 mmol/L) in blood serum. Kidneys are responsible for managing potassium balance in the body by regulating its excretion as well as its intake. A person is prone to develop hyperkalemia when the consumption of potassium exceeds that of kidneys’ potential to excrete it. The right amount of potassium and sodium in the body play a vital role in normal functioning of the myocardium.Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2406
Hyperkalemia can occur due to congestive heart failure, chronic kidney disease, or diabetic kidney disease. The condition can also occur when a patient receives renin-angiotensin-aldosterone system inhibitors (RAAS) in kidney disease. Abnormal levels of potassium can lead to irregular heartbeats, which can be fatal. Hyperkalemia is diagnosed by kidney functioning test, creatinine blood test, blood tests, and glucose monitoring.
Hyperkalemia Treatment Market– Dynamics
Increase in prevalence of cardiac arrhythmias and chronic kidney disease are major factors driving growth of hyperkalemia treatment market during the forecast period. According to Centers for Disease Control and Prevention (CDC) report, in 2017 around 30 million or 15% people suffer from chronic kidney diseases in the U.S. Increasing number of people suffering from lifestyle-associated diseases also leads to high prevalence of hyperkalemia, which in turn boost growth of the market.
Hyperkalemia Treatment Market – Regional Insights
On the basis of geography, the global hyperkalemia treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global hyperkalemia treatment market followed by Europe during the forecast period.
The U.S. holds a dominant position in North America market due to development in healthcare infrastructure, and Unhealthy lifestyle of U.S of citizen. As incidence of hyperkalemia has been reported anywhere from 2.6% to 3.2% which is highest among others region.
Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2406
Furthermore, Asia Pacific hyperkalemia treatment market is expected to witness significant growth due increasing launches of drugs for the treatment of hyperkalemia. For instance, In May 2018, The U.S. Food and Drug Administration (U.S FDA) approved AstraZeneca’s, Lokelma a drug that is insoluble, non-absorbed sodium zirconium silicate, oral suspension and acts as a highly-selective potassium-removing agent for the treatment of hyperkalemia in adults.
Similarly, in October 2015, the U.S FDA approved Relypsa, Inc.’s., Veltassa a drug to treat hyperkalemia.
Hyperkalemia Treatment Market - Competitive Landscape
Major players operating in the hyperkalemia treatment market include, AstraZeneca, Klarvoyant Biogenics Pvt. Ltd, Concordia Pharmaceuticals Inc, Steadfast MediShield Pvt. Ltd, Perrigo Company plc, AdvaCare Pharma, Eli Lilly and Company, Carolina Medical Products, Relypsa, Inc., RSM Kilitch Pharma Pvt. Ltd, Novel Laboratories, and others.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperkalemia Treatment Market, by Drug Type (IV Calcium, Insulin, Sodium Bicarbonate, Beta2 Agonist, Diuretics, Sodium Polystyrene Sulfonate, Others), by Route of Administration (Oral and Intravenous, Inhalation, Rectal) here
News-ID: 1749339 • Views: …
More Releases from Coherent Market Insights
Global Spastic Paraplegia 50 Market Huge Growth in Future Scope 2024-2031 | Pfiz …
Coherent Market Insights introduces new research on the Global Spastic Paraplegia 50 Market covering the micro level of analysis by competitors and key business segments (2024-2031). This report study encompasses a thorough examination of diverse segments, including opportunities, size, development, innovation, sales, and overall growth trajectory of major players. The research is carried out on primary and secondary statistical sources, providing a blend of qualitative and quantitative insights. The report…
Global Multiplex Assay Market Growth in Future Scope 2024-2031 | Luminex Corpora …
Coherent Market Insights introduces new research on the Global Multiplex Assay Market covering the micro level of analysis by competitors and key business segments (2024-2031). This report study encompasses a thorough examination of diverse segments, including opportunities, size, development, innovation, sales, and overall growth trajectory of major players. The research is carried out on primary and secondary statistical sources, providing a blend of qualitative and quantitative insights. The report also…
Delivery Beds Market 2024 Business Outlook, Critical Insights, Opportunities | A …
★ Synopsis Of The Report
A new study titled Delivery Beds Market 2024, published by The Coherent Market Insights, provides information on regional and global markets that is anticipated to increase in value between 2024 and 2031. The extensive research on the global Delivery Beds Market offers important insights into the market's shifting dynamics, value chain analysis, well-known investment hotspots, competitive scenarios, regional landscape, and major segments. It also offers a…
Future Growth : Global Artificial Intelligence in Oncology Market Opportunities, …
★ Synopsis Of The Report
A new study titled Global Artificial Intelligence in Oncology Market 2024, published by The Coherent Market Insights, provides information on regional and global markets that is anticipated to increase in value between 2024 and 2031. The extensive research on the global Global Artificial Intelligence in Oncology Market offers important insights into the market's shifting dynamics, value chain analysis, well-known investment hotspots, competitive scenarios, regional landscape, and…
More Releases for Hyperkalemia
Hyperkalemia Treatment Market 2022-2028 Global Industry Development Trends and A …
The latest Hyperkalemia Treatment Market study offers an all-inclusive analysis of the major strategies, corporate models, and market shares of the most noticeable players in this market. The study offers a thoroughanalysis of the key persuading factors, market figures in terms of revenues, segmental data, regional data, and country-wise data. This study can be described as most wide-ranging documentation that comprises all the aspects of the evolving Hyperkalemia Treatment Market.
Kidneys…
Global Hyperkalemia Supplement Market, Size, Share, Analysis Report & Forecast t …
The global hyperkalemia treatment market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the market is the increasing chronic diseases such as acute hyperkalemia and chronic hyperkalemia due to other ailments such as diabetes, consumption of high potassium diets, and many other things. As per the National Kidney Foundation, more than 37 million people in the United States have…
Hyperkalemia Treatment Market Technology, Recent Trends, Future Growth Analysis …
Nadroparin is an anticoagulant that belongs to the low molecular weight heparins class of medicines (LMWHs). Nadroparin is used to avoid thromboembolic disorders (deep vein thrombosis and pulmonary embolism) and to treat deep vein thrombosis in general and orthopedic surgery. It's also used to treat unstable angina and non-Q wave myocardial infarction, as well as to prevent clotting during hemodialysis. The global Nadroparin Calcium market size is projected to reach…
Hyperkalemia Therapeutics - Pipeline Analysis 2018 | Ardelyx, Inc., Relypsa
Hyperkalemia is referred to as increased levels of potassium in blood which results in cardiac arrest and death. Potassium levels above 5.1 mEq/l are considered as the hyperkalemia condition.
Download the sample report @ https://www.pharmaproff.com/request-sample/1155
The main causes of hyperkalemia are potassium sifting out of cells into the blood circulation, adrenal gland diseases, kidney dysfunction, uncontrolled diabetes, breakdown of muscle tissue and red blood cells. Hyperkalemia causes abnormal heart rhythms and…
Hyperkalemia Market: Overview, Competitive analysis Market growth and Forecast 2 …
Hyperkalemia Market report offers exhaustive Insight of the pipeline (being worked on) therapeutics situation and development prospects crosswise over Hyperkalemia advancement. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Get Sample PDF of report at:
https://www.marketreportsworld.com/enquiry/request-sample/10919314
Segmentations: -
Hyperkalemia market is segmented on the basis…
Late-Stage Chronic Kidney Disease Induced Hyperparathyroidism, Hyperphosphatemia …
An up-to-date research report has been disclosed by Market Research Hub highlighting the title “OpportunityAnalyzer: Late-Stage Chronic Kidney Disease-Opportunity Analysis and Forecasts to 2026” which focus on three major CKD-induced comorbidities: hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK). The major barrier to CKD market growth over the 2016-2026 forecast period is the loss of patent exclusivity of major drugs in the HPT, HP space. However, the decline in sales will…